NetworkNewsBreaks – Pressure BioSciences Inc. (P
Post# of 1354
(Total Views: 341)
Posted On: 11/17/2021 3:23:53 PM
NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Releases Q3 2021 Financial Report
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, has reported its third-quarter 2021 financial numbers. The company noted that the report, which is for the period ended Sept. 30, 2021, shows operational and technical achievements that set the stage for major growth and profitability expected in 2022. Highlights of the report include total revenue for Q3 2021 reaching $518,000, instrumental sales totaled $274,200, with consumable sales for the quarter topping $46,000. Year-to-date numbers shows solid growth for the year, with total revenue for the year to date totaling $1,687,000, a 60% increase from $1,056,000 from the same period the year before. In addition, instrument sales for the year-to-date reached $989,500, a 74% increase from the year before, while consumable sales were up by 23%, totaling $191,400. “Despite supply chain issues adversely affecting operations, our Q3 2021 financial results were effectively on par with the strong results of Q3 2020,” said PBIO director of sales and marketing John B. Hollister in the press release. “Importantly, our 2021 YTD financial results, including total revenue, instrument & consumable sales, and BaroFold/UST services, maintained our strong improvement trend compared to the same nine-month period in 2020. Significantly, anticipation for our eco-friendly agrochemical product sales in Q4 2021, followed by the release of our much-anticipated UST platform for leasing and licensing in the early part of 2022 continues to build. We are receiving numerous unsolicited calls every week from a variety of markets regarding our product introduction timetable to help deliver better nanoemulsified products via the UST process. We are very excited about the expected impact we believe our UST platform release will have in 2022.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, has reported its third-quarter 2021 financial numbers. The company noted that the report, which is for the period ended Sept. 30, 2021, shows operational and technical achievements that set the stage for major growth and profitability expected in 2022. Highlights of the report include total revenue for Q3 2021 reaching $518,000, instrumental sales totaled $274,200, with consumable sales for the quarter topping $46,000. Year-to-date numbers shows solid growth for the year, with total revenue for the year to date totaling $1,687,000, a 60% increase from $1,056,000 from the same period the year before. In addition, instrument sales for the year-to-date reached $989,500, a 74% increase from the year before, while consumable sales were up by 23%, totaling $191,400. “Despite supply chain issues adversely affecting operations, our Q3 2021 financial results were effectively on par with the strong results of Q3 2020,” said PBIO director of sales and marketing John B. Hollister in the press release. “Importantly, our 2021 YTD financial results, including total revenue, instrument & consumable sales, and BaroFold/UST services, maintained our strong improvement trend compared to the same nine-month period in 2020. Significantly, anticipation for our eco-friendly agrochemical product sales in Q4 2021, followed by the release of our much-anticipated UST platform for leasing and licensing in the early part of 2022 continues to build. We are receiving numerous unsolicited calls every week from a variety of markets regarding our product introduction timetable to help deliver better nanoemulsified products via the UST process. We are very excited about the expected impact we believe our UST platform release will have in 2022.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼